Imcivree
Total Payments
$14.1M
Transactions
4,723
Doctors
1,077
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $6.1M | 3,222 | 970 |
| 2022 | $5.1M | 1,275 | 167 |
| 2021 | $3.0M | 226 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.7M | 2,799 | 97.2% |
| Honoraria | $281,600 | 213 | 2.0% |
| Food and Beverage | $67,875 | 1,557 | 0.5% |
| Travel and Lodging | $38,396 | 105 | 0.3% |
| Consulting Fee | $9,163 | 6 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,187 | 1 | 0.0% |
| Education | $1,666 | 42 | 0.0% |
Payments by Type
Research
$13.7M
2,799 transactions
General
$401,887
1,924 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RM-493-034 | Rhythm Pharmaceuticals, Inc. | $3.0M | 0 |
| RM-493-035 | Rhythm Pharmaceuticals, Inc. | $2.4M | 0 |
| RM-493-014 | Rhythm Pharmaceuticals, Inc. | $2.3M | 0 |
| RM-493-022 | Rhythm Pharmaceuticals, Inc. | $2.0M | 0 |
| RHYTH001_RM 493-040_80072978 | Rhythm Pharmaceuticals, Inc. | $768,484 | 0 |
| RM-493-030 | Rhythm Pharmaceuticals, Inc. | $652,003 | 0 |
| RM-493-037/RM-493-022/RM-493-033 | Rhythm Pharmaceuticals, Inc. | $402,548 | 0 |
| RM-493-023 | Rhythm Pharmaceuticals, Inc. | $394,051 | 0 |
| RM-493-029 | Rhythm Pharmaceuticals, Inc. | $359,586 | 0 |
| RM-493-037/RM-493-022 | Rhythm Pharmaceuticals, Inc. | $245,882 | 0 |
| RM-493-014/RM-493-022 | Rhythm Pharmaceuticals, Inc. | $212,491 | 0 |
| RM-493-022/ RM-493-014 | Rhythm Pharmaceuticals, Inc. | $202,835 | 0 |
| RM-493-033 | Rhythm Pharmaceuticals, Inc. | $194,556 | 0 |
| RM-493-037 | Rhythm Pharmaceuticals, Inc. | $140,511 | 0 |
| RM-493-037/RM-493-033/RM-493-022 | Rhythm Pharmaceuticals, Inc. | $122,313 | 0 |
| RM-493-013 | Rhythm Pharmaceuticals, Inc. | $91,949 | 0 |
| RM-493-033/RM-493-022 | Rhythm Pharmaceuticals, Inc. | $83,888 | 0 |
| RM-493-023/RM-493-014 | Rhythm Pharmaceuticals, Inc. | $30,897 | 0 |
| RM-493-030/RM-493-022 | Rhythm Pharmaceuticals, Inc. | $30,469 | 0 |
| RM-493-037/RM-493-033 | Rhythm Pharmaceuticals, Inc. | $27,606 | 0 |
Top Doctors Receiving Payments for Imcivree — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatrics | Covington, LA | $3,706 | 7 |
| , MD | Family Medicine | Katy, TX | $3,532 | 6 |
| , MD | Endocrinology, Diabetes & Metabolism | Worcester, MA | $3,434 | 7 |
| , M.D | Pediatric Endocrinology | Marshfield, WI | $3,150 | 4 |
| , MD | Pediatric Endocrinology | Orange, CA | $2,837 | 5 |
| , MD | Obesity Medicine | Chapel Hill, NC | $2,835 | 1 |
| , MD, PHD | Ophthalmology | Chapel Hill, NC | $2,600 | 3 |
| , M.D., M.P.H | Pediatrics | Raleigh, NC | $2,113 | 11 |
| , M.D | Endocrinology, Diabetes & Metabolism | Mcallen, TX | $1,788 | 3 |
| , M.D | Pediatrics | Fairfield, OH | $1,746 | 3 |
| , MD | Pediatrics | Marshfield, WI | $1,275 | 1 |
| , M.D | Pediatric Endocrinology | Edinburg, TX | $1,230 | 3 |
| , M.D | Surgery | Washington, DC | $1,192 | 3 |
| , M.D | Pediatric Endocrinology | Amarillo, TX | $974.03 | 3 |
| , M.D | Obesity Medicine | Kansas City, MO | $931.36 | 6 |
| , MD | Pediatric Endocrinology | Riverside, CA | $565.02 | 19 |
| , D.O | Endocrinology, Diabetes & Metabolism | Chandler, AZ | $548.89 | 7 |
| , MD | Clinical Genetics (M.D.) | Aurora, CO | $516.00 | 1 |
| , M.D., PH.D | Clinical Genetics (M.D.) | Kansas City, KS | $500.00 | 1 |
| , M.D | Pediatrics | Philadelphia, PA | $483.00 | 1 |
| , N.P | Nurse Practitioner | Riverside, CA | $476.25 | 21 |
| , MD | Endocrinology, Diabetes & Metabolism | Chandler, AZ | $455.93 | 7 |
| , M.D., PH.D | Pediatric Endocrinology | San Diego, CA | $400.00 | 1 |
| , M.D | Pediatrics | Charleston, WV | $397.02 | 5 |
| Joanna Lis | — | Brooklyn, NY | $375.00 | 3 |
Ad
Manufacturing Companies
- Rhythm Pharmaceuticals, Inc. $14.1M
Product Information
- Type Drug
- Total Payments $14.1M
- Total Doctors 1,077
- Transactions 4,723
About Imcivree
Imcivree is a drug associated with $14.1M in payments to 1,077 healthcare providers, recorded across 4,723 transactions in the CMS Open Payments database. The primary manufacturer is Rhythm Pharmaceuticals, Inc..
Payment data is available from 2021 to 2023. In 2023, $6.1M was paid across 3,222 transactions to 970 doctors.
The most common payment nature for Imcivree is "Unspecified" ($13.7M, 97.2% of total).
Imcivree is associated with 20 research studies, including "RM-493-034" ($3.0M).